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Role of the complement components C5 and C3a in a
mouse model of myocardial ischemia and reperfusion
injury
Die Rolle der Komplementfaktoren C5 und C3a in einem Mausmodell
der myokardialen Ischämie und Reperfusion
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Objective: Ischemic heart disease is the leading cause of death world-
wide. The complement system plays a major role in inflammation and
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Methods: We performed experimental MI/R with 30 min of ischemia
and 4 hr of reperfusion in 8–12 wk old C57BL/6 (WT) mice. Systemic
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(C3aRA). Since the C3aRA induces neutropenia that resolves within
120 min, we administered C3aRA at two different time points in two
separate groups: 30 min prior to reperfusion within the neutropenic
time frame and 120 min prior to reperfusion, when the neutropenia
had resolved, but C3aRA remained active. Following MI/R, cardiac
function was assessed via echocardiography, serum troponin I concen-
trations were measured as an index of myocardial cell death and
myocardial inflammation was determined via myocardial polymorpho-
nuclear leukocyte (PMN) infiltration.
Results: In wild type mice, MI/R significantly decrease myocardial
ejection fraction and increased serum troponin I levels and myocardial
PMN infiltration compared to sham-operated animals. Systemic C5 in-
hibition, 30 min prior to reperfusion, significantly protected mice from
MI/R injury, confirming an important role for C5 in murine MI/R injury.
Treatment with the C3aRA, 30 min prior to reperfusion (i.e., within the
neutropenictimeframe),protectedmicesignificantlyfromMI/Rrelated
injury. In contrast, administration of the C3aRA 120 min prior to reper-
fusion,whentheneutropeniahadresolved,butC3aRAremainedactive,
did not prevent MI/R injury.
Conclusions: These results confirm an important role for C5 cleavage
in murine MI/R injury. At the same time, they suggest a minimal role
forC3a,sinceneutropeniaratherthanC3areceptorantagonismappears
to be responsible for C3aRA related amelioration in MI/R injury. While
C5 inhibition in the clinical setting of MI/R does not appear to be
therapeutic,ourresultsraisethepossibilitythatinhibitionofeitherC5a
orC5b-9maybemoreadvantageousthaninhibitionofC3aorcomplete
inhibition of C5 in humans.
Keywords: ischemia, reperfusion, I/R, cardiac, myocardial, heart,
ischemic heart disease, C5, C3a, complement
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Einleitung: Die koronare Herzerkrankung ist weltweit die führende To-
desursache. Das Komplementsystem spielt eine wichtige Rolle bei der
Entzündungsreaktion und dem Gewebeschaden nach myokardialer
IschämieundReperfusion(MI/R).DieInhibitiondesKomplementfaktors
C5hatteinklinischenStudienunterschiedlicheErgebnissegezeigt,und
die Rolle von Komplementfaktoren, die oberhalb der C5-Spaltung in
der Komplementkaskade liegen (z.B. C3a), wurde für MI/R nicht er-
forscht. Daher untersuchten wir die Rolle von C5 und C3a in einem
MI/R-Mausmodell.
Methoden: Wir führten in 12 Wochen alten C57BL/6 (WT)-Mäusen ex-
perimentell MI/R mit 30 min Ischämie und 4 h Reperfusion durch.
Systemische Inhibition der Komplementfaktoren C5 oder C3a wurde
mittels eines anti-C5 monoklonalen Antikörpers (BB5.1) 30 min vor der
ReperfusionodermiteinemC3a-Rezeptorantagonist(C3aRA)durchge-
führt. Da der C3aRA eine Neutropenie induziert, die innerhalb von
120 min abgeklungen ist, verabreichten wir den C3aRA in zwei unter-
schiedlichen Versuchsgruppen zu zwei Zeitpunkten: 30 min vor der
Reperfusion, innerhalb der Neutropenie, und 120 min vor der Reperfu-
sion, wenn die Neutropenie abgeklungen war, aber der C3aRA noch
aktiv war. Nach MI/R untersuchten wir die kardiale Funktion mittels
Echokardiographie, bestimmten die Serumkonzentration von Troponin
I als Zeichen myokardialen Zelluntergangs und die myokardiale Infiltra-
tion mit Polymorphonukleären Zellen (PMN) als Maß myokardialer In-
flammation.
Ergebnisse:WT-MäusehattennachMI/RimVergleichzusham-operier-
tenMäusensignifikantreduzierteEjektionsfraktionen,währendTroponin
I und die myokardiale PMN-Infiltration signifikant erhöht waren. Syste-
mische C5-Inhibierung 30 min vor der Reperfusion schützte Mäuse si-
gnifikant vor MI/R-Schädigung und bestätigt damit eine wichtige Rolle
von C5 in MI/R im Mausmodell. Eine Behandlung mit dem C3aRA 30
min vor der Reperfusion, während der neutropenischen Phase,
schütztedieMäusesignifikantvorMI/R-Schädigung.EineVerabreichung
des C3aRA 120 min vor der Reperfusion, wenn die Neutropenie abge-
klungen war, aber der C3aRA noch aktiv war, verhinderte allerdings
keine MI/R-Schädigung.
Fazit: Diese Ergebnisse bestätigen eine wichtige Rolle für C5 bei MI/R
im Mausmodell. Die durch den C3aRA verursachte Neutropenie, und
nicht der C3a-Rezeptorantagonismus, scheint für die Abschwächung
desMI/R-Schadensverantwortlichzusein.DamitscheintC3abeiMI/R
im Mausmodell nur eine untergeordnete Rolle zu spielen. Da die Inhibi-
tion des Komplementfaktors C5 in klinischen Studien nicht erfolgreich
war, sprechen unsere Ergebnisse dafür, dass die Inhibition von C5a
oder C5b-9 in klinischen Studien erfolgversprechender sein könnte als
die Inhibition von C3a oder eine komplette Inhibition von C5.
Schlüsselwörter: Ischämie, Reperfusion, I/R, kardial, myokardial, Herz,
koronare Herzerkrankung, C5, C3a, Komplement
Introduction
Ischemic heart disease is the leading cause of death in
developed countries worldwide [1]. Though reperfusion
of the hypoxic myocardial tissue after ischemia is critical
for reoxygenation and organ salvage, it also results in
myocardial ischemia and reperfusion (MI/R) injury,
causingsignificantmyocardialdamageofthereperfused
tissue [2], [3], [4]. During ischemia, myocardial cells un-
dergointrinsicchangesleadingtoperturbationsinsurface
molecule expression and the formation of neoantigens,
making the affected cells targets for the innate immune
system[2].Thisphenomenonremainsasignificantbarrier
to the otherwise restorative potential of reperfusion
therapy in ischemic heart disease.
Overthelast30years,thecomplementsystemhasbeen
shown to play a major role in myocardial inflammation
and tissue injury following MI/R [2], [3], [4], [5], [6].
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Diagram outlining the three complement pathways. MBL = mannose-binding lectin; MASP = MBL-associated serine protease;
TCC = terminal complement complex; MAC = membrane attack complex.
Complement, part of the innate immune system, can be
activated by at least three separate pathways: the clas-
sical, alternative, and lectin pathways (Figure 1). The
mechanism of ischemia and reperfusion (I/R) injury re-
sults from the recognition of neoantigens that have been
exposed during ischemia with subsequent initiation of
complement.Intheclassicalpathway,naturalantibodies
interact with neoantigens and form antigen-antibody
complexes. The complement subcomponent C1q can
initiate classical pathway activation by recognition of
these antigen-antibody complexes (Figure 1); however,
C1q can also recognize apoptotic cells in the absence of
antibodies [7], [8], [9]. The lectin pathway is initiated by
recognition of exposed carbohydrates/ligands by man-
nose-binding lectin (MBL) and/or ficolins (Figure 1) [10],
[11]. C3b deposition from either the classical or lectin
pathwaycaninitiateactivationofthealternativepathway
and serves to amplify complement activation (i.e., tick-
over amplification) [3], [4], [12]. While the lectin and al-
ternative complement pathways are historically known
to activate complement in an antibody independent
manner, our group recently demonstrated that MBL also
interacts with IgM to activate the lectin complement
pathway[13]andthatlectincomplementpathwayactiva-
tion in myocardial MI/R is dependent on both MBL and
IgM [14]. Similar observations by others, also support an
Ab-dependent activation of the MBL-dependent lectin
pathway [15]. All three activated complement pathways
converge to generate two structurally dissimilar, yet
functionally similar C3 convertases (Figure 1). Each C3
convertase cleaves C3 into two fragments, the anaphylo-
toxin C3a and the complement component C3b, which
binds to the C3 convertase to form a C5 convertase, fol-
lowed by cleavage of C5 into C5a and C5b [3], [4]. The
anaphylatoxin C5a is a potent activator of inflammation
andachemoattractantforinflammatorycellpopulations,
includingpolymorphonuclearleukocytes(PMNs),whereas
C5b can interact with C6, C7, C8, and multiple C9 units
to form the terminal complement complex C5b-9. C5b-9
formation can lead to cellular activation or lysis of anu-
cleated cells [3], [4]. Thus, complement related tissue
injurymaybeinduceddirectlybytheterminalcomplement
complex C5b-9, by cell-bound ligands, including C4b and
C3b, and by the anaphylatoxins C3a and C5a, which can
amplify injury by attracting and activating inflammatory
cells [3], [4].
ToattenuateMI/Rinjuryexperimentally,thecomplement
system has been inhibited on several levels. Previous
studies have shown that C5 inhibition protects against
I/R injury of the brain [16], lung [17] and myocardium
[18]. However, in clinical studies, systemic C5 inhibition
with pexelizumab has resulted in mixed results. Early
studies suggested a pexelizumab-related protection with
impressive improvement of the survival rate in MI and
coronary artery bypass graft surgery [19], [20], [21]. As
a result, two large Phase 3 clinical trials were initiated,
which showed a non-significant trend toward a positive
effect of the study drug, but failed to meet the primary
endpoints [22], [23], [24].
While the anaphylatoxin C5a has been shown to be a
potent activator of inflammation [3], [4], the role of the
anaphylatoxin C3a, an early complement component
upstream from C5 cleavage, has shown mixed results in
animal models of I/R injury. In mouse models of renal
and cerebral I/R injury, C3a appears to play a key role in
mediating I/R injury [25], [26], while Proctor et al. sug-
gested only a minor role for C3a in GI/R injury [27]. Des-
pite this, the role of the anaphylatoxin C3a in MI/R injury
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of C5 and C3a in a mouse model of MI/R injury.
Methods
Administration of anti-C5 monoclonal
antibody and C3a receptor antagonist
All animals used were male mice aged 8–12 wk old.
C57BL/6 [wild type (WT)] mice were obtained from
Charles River Laboratories (Wilmington, MA, USA). All
procedures were reviewed and conducted in accordance
with the Institute’s Animal Care and Use Committee
(IACUC). Experiments were performed according to the
standards and principles set forth in the National Insti-
tutesofHealth[28].Onegroupofmicewasanesthetized
with isoflurane and injected via the penile vein with
1 mg/kg of a C3a receptor antagonist (C3aRA; Calbio-
chem, San Diego, CA, USA) 120 min prior to reperfusion
to achieve C3a receptor antagonism and avoid the asso-
ciated neutropenia as described [27]. Two additional
groups were treated during the MI/R procedure 30 min
prior to reperfusion with 1 mg/kg of the C3aRA or
50 mg/kg of a C5 monoclonal antibody (BB5.1), as we
have described [16]. Sham operated mice and mice un-
dergoingMI/RwithoutC3aRAorC5monoclonalantibody
treatment, received vehicle (e.g. PBS).
Experimental MI/R
ExperimentalMI/Rwasperformedaswehavepreviously
described[5],[14],[29].Inbrief,micewereinitiallyanes-
thetizedwithsodiumpentobarbital(60mg/kg,i.p.),intub-
ated and ventilated with positive pressure on a small
animal ventilator (Model 683, Harvard Apparatus, Hollis-
ton, MA, USA). Anesthesia was then maintained with iso-
flurane (1–3 MAC). After creating a longitudinal incision
through the skin of the lateral left chest, the overlying
chest muscles were retracted using 5-0 black-braided
silk suture (Ethicon, Somerville, NJ, USA). The chest was
opened within the third intercostal space, and the chest
wall retracted using 5-0 black-braided silk suture (Figure
2 B). An 8-0 black-braided silk suture (U.S. Surgical, Nor-
walk, CT, USA) was passed underneath the left anterior
descending coronary artery (LAD), 2 mm from the tip of
the left atrium. To induce ischemia, a 1- to 2-mm piece
of 0-0 suture (Deknatel, Fall River, MA, USA) was placed
on the LAD, and the 8-0 suture tightened to occlude the
artery (Figure 2 A and B). After 30 min of ischemia, the
ligation was loosened and the 0-0 suture removed and
the myocardium reperfused for 4 hr. The chest wall was
closedusing5-0black-braidedsilksutures.Theoverlying
chest muscles were allowed to retract, and the skin was
sutured using 5-0 black-braided silk sutures. An electro-
cardiogram (modified lead III) was evaluated before,
during and after ischemia and used to establish compar-
ableischemiaandreperfusionineverymouse.Onlymice
demonstrating increased ST elevation (>4 mm) during
ischemia were included in the study.
Figure 2: Experimental MI/R
2A: Diagram outlining the location of left anterior descending
artery(LAD)-ligationanddirectionofmyocardialsections/slices.
2B: Intraoperative picture of surgical approach through third
intercostal space to the heart and LAD-ligation. 5-0
black-braided silk sutures are used to retract third and fourth
rib. Myocardial ischemia is induced by LAD-ligation using 8-0
black-braided silk suture over a 1- to 2-mm piece of 0-0 suture
placed for protection on the LAD to prevent the 8-0 suture from
cutting into the LAD and myocardium.
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Previous work from our laboratory has shown that
myocardial damage via infarct analysis is directly correl-
ated with loss of left ventricular function as measured by
echocardiography [5]. Therefore, in the present study,
echocardiography measurements were used to assess
cardiac function. Echocardiography was performed 4 hr
after reperfusion using a Philips Sonos 5500 (Philips
Medical Systems, Bothell, WA, USA) with a 7–12 MHz
animaltransducer(AgilentTechnologies,SantaClara,CA,
USA), as we described [5], [14], [29]. Ejection fraction
(EF) was calculated by left ventricular M-mode measure-
ments and via long axis length and short axis area
measurements of the left ventricle (LV) [30], [31], [32].
ForEF,onlyM-modedataarepresented,asbothmethods
of EF measurements produced identical results.
Collection of blood and tissue
Following reperfusion and echocardiography, the chest
cavity was opened, the inferior caval vein cut, and blood
wascollectedfromthethoraciccavityasdescribedprevi-
ously[5],[14],[29].Heartswereexcisedandfixedin10%
formalin-PBS at 4°C overnight.
Serum troponin I concentrations
Serum troponin I concentrations were measured as an
index of myocardial cell death using a commercially
available ELISA kit (Life Diagnostics, West Chester, PA,
USA) as described previously [5], [14], [29], [33].
Histological sections and staining for
PMN
Heart samples were dehydrated, embedded in paraffin
and cut cranial to caudal into 7 µm sections as we de-
scribed[14],[29].Weusedcomparablesectionsforeach
heart, so the staining was performed on similar levels of
eachheart.Thus,therewasnoneedtocomparedifferent
areas of each section, as each section represents a cut
through the entire heart and each section was evaluated
in total by quantitative pixel analysis. To evaluate
myocardial PMN infiltration, sections were deparafinized
withEZ-DeWaxSolution(BioGenex,SanRamon,CA,USA)
andincubatedwithblockingbuffercontaining5%normal
sheep serum for 1–2 hr at room temperature. Primary
antibodyincubationwasperformedwithpurifiedratanti-
mouse Ly-6G monoclonal Ab (BD Pharmingen, Franklin
Lakes, NJ, USA) for 1–2 hr at room temperature [34].
Following primary antibody incubation, slides were
washed four times for 15 min with TBS-Tween and then
incubated with a secondary sheep anti-rat IRDye800 Ab
(Rockland Immunochemicals, Gilbertsville, PA, USA) for
1–2hratroomtemperature.Afterwashingfourtimesfor
15mineach,excessfluidwasremovedandtheslidewas
covered with Gel Mount (Biomeda, Foster City, CA, USA),
cover slips (Fisher Scientific, Pittsburgh, PA, USA) and
sealedafter1hrwithclearnailpolish.Ultimately,sections
were scanned for PMN infiltration with an Odyssey in-
frared imaging system (LI-COR, Lincoln, NE, USA) at 800
nm, as we validated and documented previously [14],
[29]. Myocardial sections stained for PMN deposition
were quantitatively analyzed for 4–6 animals per group
by pixel counting using ImageJ software (NIH).
Statistics
All statistical analyses of data were performed using Sig-
maStat software (SPSS, Chicago, IL, USA). All data were
evaluated using one-way ANOVA and post hoc analysis
using the Student-Newman-Keuls method. All data are
expressed as the mean ± SE and differences were con-
sidered significant at P<0.05.
Results
Echocardiography
Following 30 min of ischemia and 4 hr of reperfusion, a
significant decrease in left ventricular ejection fraction
(EF)innon-treatedWTmicecomparedtosham-operated
animals was observed (Figure 3 and Figure 4). EF before
MI/R was comparable to sham operated animals (data
not shown). Mice treated with C5 monoclonal antibody
30 min prior to reperfusion were significantly protected
fromlossofmyocardialfunctionfollowingMI/Rcompared
to non-treated mice (Figure 3 and Figure 4), suggesting
asignificantroleofC5inMI/Rinjury.TheC3aRAisknown
toinduceneutropeniathatresolveswithin120minwhile
its C3a receptor antagonism is still active [27]. MI/R in
mice treated 120 min prior to reperfusion, when the
neutropenia had resolved, but C3aRA was still active, in-
duced a significant decrease in EF compared to sham-
operated mice. In contrast, mice treated with the C3aRA
30 min prior to reperfusion were significantly protected
fromlossofmyocardialfunctionfollowingMI/R,compared
to sham-operated mice.
Serum troponin I concentrations
Serum troponin I concentrations provided biochemical
findings that confirmed and supported the echocardio-
graphic observations. Sham-operated animals did not
presentdetectableserumtroponinIconcentrations(data
notshown).Thirtyminofischemiaand4hrofreperfusion
in vehicle-treated mice significantly increased serum
troponinIconcentrations.Confirmingourechocardiograph-
ic findings, mice treated with a C5 monoclonal antibody
hadsignificantlyreducedserumtroponinIconcentrations
compared to vehicle-treated mice (Figure 5), supporting
a significant role for C5 in MI/R injury. Serum troponin I
concentrations in mice treated with C3aRA 30 min prior
to reperfusion were significantly reduced compared to
vehicle-treated mice undergoing MI/R, while administra-
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M-mode measurements were performed by echocardiography. In the upper row: sham-operated mice (Sham vehicle) and mice
that underwent MI/R with 30 of ischemia and 4 hr reperfusion (MI/R vehicle). The lower row represents animals after MI/R
treated with C5 monoclonal antibody (antiC5) 30 min prior to reperfusion (R) or with C3a receptor antagonist (C3aRA) 120 min
and 30 min prior to R, respectively.
Figure 4: Summary of ejection fraction data
Echocardiography was performed and ejection fraction (%) was calculated from the M-mode measurements as described in
Methods. Groups: vehicle-treated sham-operated mice (sham vehicle), vehicle-treated mice following 30 min of ischemia and 4
hr of reperfusion (vehicle) and mice undergoing MI/R that were treated with C5 monoclonal antibody (antiC5) 30 min prior to
reperfusion (30preR) or with C3a receptor antagonist (C3aRA) 120 min and 30 min prior to R, respectively (120preR or 30preR).
All data are mean ± SE of 4–6 animals per group. * p<0.05 compared to sham-operated animals (sham). ** p<0.05 compared
to untreated mice undergoing MI/R with 30 min of ischemia and 4 hr of reperfusion.
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Serum troponin I concentrations after MI/R were measured as described in Methods. The columns represent mice that were
vehicle-treated, mice injected with C5 monoclonal antibody (antiC5) 30 min prior to reperfusion (30preR) or with C3a receptor
antagonist (C3aRA) 120 min and 30 min prior to R, respectively (120preR or 30preR). All data are mean ± SE of 4–6 animals
per group. * p<0.05 compared to untreated mice following MI/R.
tion 120 min prior to reperfusion was not protective
(Figure 5).
Histological Sections and Staining for
PMN
PMN infiltration into the cardiac tissue as a measure of
MI/Rrelatedinflammationmirroredourechocardiograph-
ic and serum troponin I measurements (Figure 6). In tis-
suesamplesfromsham-operatedanimals,nosignificant
PMN infiltration was observed. In contrast, 30 min of
ischemia and 4 hr of reperfusion induced a significant
inflammatory response in vehicle-treated mice (Figure 6
AandB).TreatmentwithC5monoclonalantibodyattenu-
ated the inflammatory response significantly compared
to vehicle treated mice, while administration of C3aRA
attenuatedPMNinfiltrationsignificantlyonlyinthegroup
treated 30 min prior to reperfusion in the neutropenic
timeframeandnot120minpriortoreperfusionafterthe
neutropenic effect had resolved (Figure 6 A and B).
Discussion
UsingaC5monoclonalantibodyinamouseMI/Rmodel,
we confirmed a significant contribution of C5 in MI/R-in-
ducedinjury,anobservationalreadyreportedinrats[18].
Mice treated with C5 monoclonal antibody were signifi-
cantlyprotectedfromlossofmyocardialfunctionfollowing
MI/R compared to vehicle-treated mice. Since the role of
early complement components upstream from C5 cleav-
ageinMI/Rhasnotbeenelucidated,weinvestigatedthe
effect of C3aR antagonism in MI/R.
Interestingly, our results indicate that the anaphylatoxin
C3a plays only a minimal role in MI/R-induced injury. In
2001, Ames et al. identified a selective non-peptide ant-
agonist of the C3a receptor [35]. Proctor et al. showed
that the C3aRA has a strong neutropenic side effect that
resolves within 120 min, while its C3aR antagonism re-
mains active [27]. While both groups carried out in depth
pharmacological examinations of this antagonist in
models of complement activation, both in vitro and in
vivo, the mechanism of C3aRA mediated neutropenia
wasnotelucidated.Itwasspeculatedthatthiseffectwas
secondary and not related to receptor antagonism, as
strategies to deplete neutrophils and/or inhibit their ad-
hesiontolocalendotheliumalsoamelioratedsubsequent
inflammatory effects [27], [35].
Due to the temporary neutropenic side effect, we admin-
istered the C3aRA at two different time points in two
groups of mice. Mice were only protected from MI/R in-
duced cardiac injury when the C3aRA was administered
during its neutropenic time frame. Administration 120
min prior to reperfusion, when the neutropenia was re-
solved,butC3aRAisstillactive[27],didnotpreventmice
from MI/R associated injury. These data indicate that a
benefit of the C3aRA in MI/R is based on its neutropenic
side effect only, and not a result of specific C3aR antag-
onism. Troponin I concentrations and neutrophil infiltra-
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6A: Representative sections. Heart sections were stained and PMN infiltration into the myocardium was measured using an
infrared imaging system as described in Methods. Representative sections are shown from 4–6 animals per group. Upper row:
1.+2. Ab (primary and secondary antibody). Lower row: control group with 2. Ab only (secondary only antibody). Groups:
vehicle-treated sham-operated mice (sham vehicle), vehicle-treated mice that underwent MI/R with 30 min of I and 4 hr of R
(vehicle),miceundergoingMI/RandtreatedwithC5monoclonalantibody(antiC5)30minpriortoR(30preR)orwithC3areceptor
antagonist (C3aRA) 120 min and 30 min prior to R respectively (120preR or 30preR). 6B: Quantitatvie analysis of sections by
pixel count. Pictures from heart sections stained for PMNs from 4-6 animals per group were quantitatively analyzed by pixel
counting using ImageJ software. * p<0.05 compared to sham-operated animals (sham). ** p<0.05 compared to untreated mice
undergoing MI/R (MI/R vehicle).
tion into the myocardium further supported this observa-
tion.
In clinical studies, the benefit of pexelizumab, a recom-
binanthumanizedsingle-chainantibodyfragmentinhibit-
ing C5, has been controversial. In the “Phase 2 Comple-
ment Inhibition in Myocardial Infarction Treated with An-
gioplasty” (COMMA) trial, a greater than 50% reduction
in mortality at 90 days among ST-elevation MI (STEMI)
patients treated with pexelizumab, was reported [19].
Additionally, prexelizumab was beneficial in patients un-
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In contrast, prexelizumab administration did not reduce
adverse clinical outcomes in STEMI patients treated for
fibrinolysis [36]. These aforementioned results in early
clinical studies resulted in the design of 2 large Phase 3
studies: the “Assessment of Pexelizumab in Acute
Myocardial Infarction” (APEX AMI) trial [22] and the
“Pexelizumab for Reduction in Myocardial Infarction and
MortalityinCoronaryArteryBypassGraftSurgery”(PRIMO
CABG-II) study [24]. The APEX AMI trial was terminated
early due to a lower than expected mortality rate in the
placebo group. Thus, an increase in the required sample
size to maintain study power to more than 11,000 pa-
tients, compared to the previously estimated 8,500 pa-
tients would be necessary [23]. A second reason for the
premature termination, were results from the parallel
PRIMO-CABG II trial, where the primary objective was not
achieved [23], [37]. As a result, the use of pexelizumab
in clinical cardiovascular disease settings is unlikely to
be advanced.
TheanaphylatoxinsC3aandC5aarenotinitiatingfactors
ofthecomplementsystem,buttheyappeartoberespons-
ible for promoting, amplifying and perpetuating inflam-
matory reactions [3], [4], [38]. Interestingly, while the
anaphylatoxin C5a has been shown to be a potent acti-
vatorofinflammation[3],[4],thereareonlyafewstudies
investigating the role of C3a in I/R injury and none in
MI/R injury. Application of the C3aRA in a murine stroke
model resulted in significant neurological improvement
and stroke volume reduction [25]. Thus, a C3a anaphyla-
toxin-mediated mechanism in cerebral I/R injury was as-
sumed. However, since the same C3aRA was used as in
our study and was administered 45 min before ischemia
intheneutropenictimeframeoftheC3aRA,itisquestion-
able, if the observed benefit in cerebral I/R was primarily
a result of C3aR antagonism [25], [27]. In contrast to
myocardial I/R, C3a appears to play a significant role in
I/R injury of the kidneys. In a mouse model of renal I/R,
C3a generated by activation of the alternative comple-
ment pathway appears to plays a key role in mediating
I/R injury through subsequent activation of the NF-κB
system [26].
Conclusion
In conclusion, our study confirms a pathophysiologic role
forC5inMI/Rinjuryandindicatesthattheanaphylatoxin
C3a plays only a minimal role in MI/R-induced injury.
While C5 inhibition in the clinical setting of MI/R does
not appear to be therapeutic, our results raise the possi-
bility that inhibition of either C5a or C5b-9 may be more
advantageous than inhibition of C3a or complete inhib-
ition of C5 in humans to attenuate complement related
inflammation and subsequent myocardial injury.
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